Trial reportEuropean journal of nuclear medicine and molecular imaging2017
Monitoring early response to chemoradiotherapy with
Trial report in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.European journal of nuclear medicine and molecular imaging · 2022Trial
- Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.Journal of the National Cancer Institute · 2021Trial
- Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.European journal of nuclear medicine and molecular imaging · 2020Trial
- Prospective Evaluation of a Tumor Control Probability Model Based on DynamicJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Trial
- Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.Breast cancer research and treatment · 2026Article
- Predicting the hypoxic volume of head and neck tumors from fluorodeoxyglucose positron emission tomography images using artificial intelligence.Physics and imaging in radiation oncology · 2025Article
- Distinguishing benign from malignant lesions with high [European journal of nuclear medicine and molecular imaging · 2025Article
- Tumor Hypoxia on 18F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma.JAMA network open · 2024Article
- An end-to-end deep learning pipeline to derive blood input with partial volume corrections for automated parametric brain PET mapping.Biomedical physics & engineering express · 2024Article
- FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer.Journal of personalized medicine · 2022Review
- Synthesis of a 2-nitroimidazole derivative N-(4-[EJNMMI radiopharmacy and chemistry · 2022Article
- Phantom Validation of a Conservation of Activity-Based Partial Volume Correction Method for Arterial Input Function in Dynamic PET Imaging.Tomography (Ann Arbor, Mich.) · 2022Article
- Value of PET imaging for radiation therapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Review
- Article
- Article
- Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives.European journal of nuclear medicine and molecular imaging · 2021Review
- Quantitative imaging for radiotherapy purposes.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020Review
- Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment.The British journal of radiology · 2020Article
- Synthesis and Preliminary Evaluation of a NovelFrontiers in oncology · 2020Article
- Imaging science and development in modern high-precision radiotherapy.Physics and imaging in radiation oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeThere is growing recognition that biologic features of the tumor microenvironment affect the response to cancer therapies and the outcome of cancer patients. In head and neck cancer (HNC) one such feature is hypoxia. We investigated the utility of EXPERIMENTAL
designSeventy-two HNC patients underwent FMISO dPET scans in a customized immobilization mask (0-30 min dynamic acquisition, followed by 10 min static acquisitions starting at ∼95 min and ∼160 min post-injection) at baseline and early into treatment where patients have already received one cycle of chemotherapy and anywhere from five to ten fractions of 2 Gy per fraction radiation therapy. Voxelwise pharmacokinetic modeling was conducted using an irreversible one-plasma two-tissue compartment model to calculate surrogate biomarkers of tumor hypoxia (k
resultsOne hundred and thirty-five lesions in total were analyzed. TBR, k
conclusionPharmacokinetic modeling of FMISO dynamic PET reveals a more detailed characterization of the tumor microenvironment and assessment of response to chemoradiotherapy in HNC patients than a single static image does. In a clinical trial where absence of hypoxia in primary tumor and lymph nodes would lead to de-escalation of therapy, the observed disagreement between visual analysis and pharmacokinetic modeling results would have affected patient management in <20% cases. While simple static PET imaging is easily implemented for clinical trials, the clinical applicability of pharmacokinetic modeling remains to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.